455 related articles for article (PubMed ID: 23369448)
1. Contribution of uric acid to cancer risk, recurrence, and mortality.
Fini MA; Elias A; Johnson RJ; Wright RM
Clin Transl Med; 2012 Aug; 1(1):16. PubMed ID: 23369448
[TBL] [Abstract][Full Text] [Related]
2. U-shaped association of uric acid to overall-cause mortality and its impact on clinical management of hyperuricemia.
Crawley WT; Jungels CG; Stenmark KR; Fini MA
Redox Biol; 2022 May; 51():102271. PubMed ID: 35228125
[TBL] [Abstract][Full Text] [Related]
3. The role of xanthine oxidoreductase and uric acid in metabolic syndrome.
Battelli MG; Bortolotti M; Polito L; Bolognesi A
Biochim Biophys Acta Mol Basis Dis; 2018 Aug; 1864(8):2557-2565. PubMed ID: 29733945
[TBL] [Abstract][Full Text] [Related]
4. The Role of Oxidative Stress in Hyperuricemia and Xanthine Oxidoreductase (XOR) Inhibitors.
Liu N; Xu H; Sun Q; Yu X; Chen W; Wei H; Jiang J; Xu Y; Lu W
Oxid Med Cell Longev; 2021; 2021():1470380. PubMed ID: 33854690
[TBL] [Abstract][Full Text] [Related]
5. Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview.
Chen C; Lü JM; Yao Q
Med Sci Monit; 2016 Jul; 22():2501-12. PubMed ID: 27423335
[TBL] [Abstract][Full Text] [Related]
6. Xanthine Oxidase and its Role as Target in Cardiovascular Disease: Cardiovascular Protection by Enzyme Inhibition?
Schuchardt M; Herrmann J; Tolle M; van der Giet M
Curr Pharm Des; 2017; 23(23):3391-3404. PubMed ID: 28413972
[TBL] [Abstract][Full Text] [Related]
7. An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia.
Bove M; Cicero AF; Veronesi M; Borghi C
Vasc Health Risk Manag; 2017; 13():23-28. PubMed ID: 28223818
[TBL] [Abstract][Full Text] [Related]
8. Metabolic syndrome and cancer risk: The role of xanthine oxidoreductase.
Battelli MG; Bortolotti M; Polito L; Bolognesi A
Redox Biol; 2019 Feb; 21():101070. PubMed ID: 30576922
[TBL] [Abstract][Full Text] [Related]
9. Hepatocyte-Specific Ablation or Whole-Body Inhibition of Xanthine Oxidoreductase in Mice Corrects Obesity-Induced Systemic Hyperuricemia Without Improving Metabolic Abnormalities.
Harmon DB; Mandler WK; Sipula IJ; Dedousis N; Lewis SE; Eckels JT; Du J; Wang Y; Huckestein BR; Pagano PJ; Cifuentes-Pagano E; Homanics GE; Van't Erve TJ; Stefanovic-Racic M; Jurczak MJ; O'Doherty RM; Kelley EE
Diabetes; 2019 Jun; 68(6):1221-1229. PubMed ID: 30936145
[TBL] [Abstract][Full Text] [Related]
10. Uric acid and diabetes: Is there a link?
Katsiki N; Papanas N; Fonseca VA; Maltezos E; Mikhailidis DP
Curr Pharm Des; 2013; 19(27):4930-7. PubMed ID: 23278493
[TBL] [Abstract][Full Text] [Related]
11. Friend or Foe? An Unrecognized Role of Uric Acid in Cancer Development and the Potential Anticancer Effects of Uric Acid-lowering Drugs.
Mi S; Gong L; Sui Z
J Cancer; 2020; 11(17):5236-5244. PubMed ID: 32742469
[TBL] [Abstract][Full Text] [Related]
12. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity.
Furuhashi M
Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E827-E834. PubMed ID: 32893671
[TBL] [Abstract][Full Text] [Related]
13. Purine Metabolite Signatures and Type 2 Diabetes: Innocent Bystanders or Actionable Items?
Romeo GR; Jain M
Curr Diab Rep; 2020 Jun; 20(8):30. PubMed ID: 32519009
[TBL] [Abstract][Full Text] [Related]
14. Allopurinol, an inhibitor of uric acid synthesis--can it be used for the treatment of metabolic syndrome and related disorders?
Suzuki I; Yamauchi T; Onuma M; Nozaki S
Drugs Today (Barc); 2009 May; 45(5):363-78. PubMed ID: 19584965
[TBL] [Abstract][Full Text] [Related]
15. Plasma xanthine oxidoreductase (XOR) activity in patients who require cardiovascular intensive care.
Shibata Y; Shirakabe A; Okazaki H; Matsushita M; Goda H; Shigihara S; Asano K; Kiuchi K; Tani K; Murase T; Nakamura T; Kobayashi N; Hata N; Asai K; Shimizu W
Heart Vessels; 2020 Oct; 35(10):1390-1400. PubMed ID: 32342210
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of hyperuricemia and the relationship between serum uric acid and metabolic syndrome in the Asian Mongolian area.
You L; Liu A; Wuyun G; Wu H; Wang P
J Atheroscler Thromb; 2014; 21(4):355-65. PubMed ID: 24401703
[TBL] [Abstract][Full Text] [Related]
17. Associations Between Serum Uric Acid Concentrations and Cardiometabolic Risk and Renal Injury in Obese and Overweight Children.
Özalp Kızılay D; Şen S; Ersoy B
J Clin Res Pediatr Endocrinol; 2019 Sep; 11(3):262-269. PubMed ID: 30759960
[TBL] [Abstract][Full Text] [Related]
18. Prospective study of serum uric acid levels and incident metabolic syndrome in a Korean rural cohort.
Yadav D; Lee ES; Kim HM; Choi E; Lee EY; Lim JS; Ahn SV; Koh SB; Chung CH
Atherosclerosis; 2015 Jul; 241(1):271-7. PubMed ID: 25957887
[TBL] [Abstract][Full Text] [Related]
19. Uric Acid in Metabolic and Cerebrovascular Disorders: A Review.
Cortese F; Scicchitano P; Cortese AM; Meliota G; Andriani A; Truncellito L; Calculli G; Giordano P; Ciccone MM
Curr Vasc Pharmacol; 2020; 18(6):610-618. PubMed ID: 31845632
[TBL] [Abstract][Full Text] [Related]
20. Uric Acid Metabolic Disorders in Pituitary-Target Gland Axis.
Li R; Wu B; Han M; Li M; Yang X; Zhang J; Zhang Y; Liu Y
Diabetes Metab Syndr Obes; 2024; 17():661-673. PubMed ID: 38343584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
